JANX
$24.45
Revenue | $0Mn |
Net Profits | $-23.51Mn |
Net Profit Margins | -Inf% |
Janux Therapeutics Inc’s revenue fell -100% since last year same period to $0Mn in the Q1 2025. On a quarterly growth basis, Janux Therapeutics Inc has generated NaN% jump in its revenue since last 3-months.
Janux Therapeutics Inc’s net profit fell -59.27% since last year same period to $-23.51Mn in the Q1 2025. On a quarterly growth basis, Janux Therapeutics Inc has generated -16.28% fall in its net profits since last 3-months.
Janux Therapeutics Inc’s net profit margin fell -Inf% since last year same period to -Inf% in the Q1 2025. On a quarterly growth basis, Janux Therapeutics Inc has generated NaN% jump in its net profit margins since last 3-months.
EPS Estimate Current Quarter | -0.46 |
EPS Estimate Current Year | -0.46 |
Janux Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.46 - a -17.79% fall from last quarter’s estimates.
Janux Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.46.
Earning Per Share (EPS) | 0 |
Janux Therapeutics Inc’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q2 2025. This indicates that the Janux Therapeutics Inc has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2025-05-08 | -0.39 | -0.38 | 2.99% |
2025-08-12 | -0.46 | 0 | 100% |